How To Invest In Cartesian Therapeutics, Inc. Stock - RNAC Share Price Today & News | Stash

Invest in Cartesian Therapeutics, Inc. on Stash

Cartesian Therapeutics, Inc., formerly Selecta Biosciences, Inc., incorporated on December 10, 2007, is a clinical-stage company, which is engaged in ribonucleic acid (RNA) cell therapies for the treatment of autoimmune diseases.

To buy fractional shares of Cartesian Therapeutics, Inc. stock, you'll need to sign up for Stash and open a personal portfolio.

Stash allows you to purchase smaller pieces of investments, called fractional shares, rather than having to pay the full price for a whole share.

Ticker: RNAC

Cartesian Therapeutics, Inc.

$8.26

-14.58%
(1W)
Jul ’26Jul ’26$9$9$10

$

1W1M1Y5Y

RNAC Performance Breakdown

Share Price

The last publicly stated price for one share of an investment, updated every approximately 20 minutes during market hours (usually business days between 9:30 a.m. and 4:00 p.m. ET).

$8.26

Today's change

This is how much an investment's price has changed over the last day of active trading. For example, if an investment's price was $10 yesterday, and today it rose to $11, you'd see a 1 day change of 10%.

-0.84%

Year to date change (YTD)

This is the performance of the investments since the start of the year, updated approximately every 20 minutes during market hours (usually business days between 9:30 a.m. and 4:00 p.m. ET).

22.19%

Dividend yield

Some investments pay you profits or interest as you hold them. These payments are called dividends, and this value represents the dollar value as a percentage of the investment's share price.

0.0

Last dividend paid

The dollar value per share that was paid out to shareholders.

N/A

Last dividend pay date

The date shareholders were paid out for the last dividend issued.

N/A

About RNAC

Cartesian Therapeutics, Inc., formerly Selecta Biosciences, Inc., incorporated on December 10, 2007, is a clinical-stage company, which is engaged in ribonucleic acid (RNA) cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase IIb clinical development for patients with generalized myasthenia gravis. Descartes-08 is designed to be an autologous anti-BCMA rCAR-T. Descartes-08 is in clinical development for autoimmune diseases, including Myasthenia gravis (MG), a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Its proprietary technology platform, RNA Armory, is designed to enable precision control and optimization of engineered cells for diverse cell therapies leveraging multiple modalities, including autologous, allogeneic, and in vivo transfection. Orphan Drug Designation by the United States Food and Drug Administration has granted Descartes-08 for the treatment of MG. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout that durably controls uric acid in refractory gout, and dissolves and removes harmful deposits of uric acid crystals in chronic tophaceous gout. SEL-212 is in a Phase I/II clinical program. The Phase I/II clinical program consists of two Phase I clinical trials and a Phase II clinical trial and is designed to evaluate the ability of SEL-212 to control uric acid levels and mitigate the formation of ADAs. SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase, for the treatment of refractory and chronic tophaceous gout.

How to buy Cartesian Therapeutics, Inc. stock on Stash

  1. Enter the amount you'd like to invest in Cartesian Therapeutics, Inc. stock, then proceed to checkout.

Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.
Cartesian Therapeutics, Inc.’s share price is determined by its bid-ask spread, which is the difference between the price that buyers are willing to pay and the price that sellers are willing to accept. Cartesian Therapeutics, Inc.’s price can fluctuate throughout the course of each trading day—when you buy Cartesian Therapeutics, Inc. through Stash, we execute the market order during our next available trading window (we have two a day). At Stash, we don’t recommend trying to predict the market when buying investments. We believe it can be a better strategy to buy quality investments you believe in, then hang onto them.

  1. Set up your investment account in just a few minutes.
    Stash offers one subscription plan: The Stash Plan.

  2. Once you’ve finished your account, your Cartesian Therapeutics, Inc. shares will be added to your new portfolio.

Once your market order of Cartesian Therapeutics, Inc. stock is complete, you'll officially be a shareholder of Cartesian Therapeutics, Inc.!

You can continue to build your portfolio by buying more stocks and funds—there are hundreds of options on Stash.